Appvance Granted Seminal U.S. Patent Enabling Fully Autonomous Test Script Generation from Natural Language

SANTA CLARA, Calif.--(BUSINESS WIRE)--Appvance, the leader in AI-driven software test automation, today announced the issuance of U.S. Patent No. 12,353,317 for “Methods for Creating Test Scripts and/or Updating a Model of an Application.” This foundational patent cements Appvance’s leadership in the field of generative AI for software testing and directly underpins the company’s GENI™ technology—the only system in the world that fully automates test script creation from English test cases, without human intervention.

This patent describes how Appvance’s AI leverages a dynamic Digital Twin—referred to in the patent as a “blueprint”—alongside one or more transformer-based large language models (LLMs), to convert manual test cases into fully executable automation scripts. The system continuously updates its model of the application and autonomously generates test scripts by mapping natural language steps to real interactions in the application. It even processes visual input via image recognition to match UI elements intelligently, allowing test cases to include text, images, or both.

“The era of record-and-play is over,” said Kevin Surace, CEO of Appvance and lead inventor on the patent. “With this patent, the industry now has a blueprint—literally and legally—for how AI can truly replace manual scripting and maintenance and obsolete all recorders. It’s a monumental step forward not just for Appvance, but for the entire QA and DevOps landscape.”

Appvance’s GENI engine, which implements this patented technology, is already in use across major enterprises, converting thousands of legacy test cases per day and enabling 90%+ reductions in labor cost and test cycle time. Unlike “AI-washed” tools that simply assist humans or automate UI element recognition, GENI performs full script generation autonomously, with no recorders, no script editing, and no test logic authoring required.

This patent sets a new industry benchmark and affirms that Appvance’s technology is not just ahead of the curve—it is the curve. For enterprises seeking to reduce cost, accelerate delivery, and improve coverage, GENI powered by this newly patented invention is the only path forward.

For more information, please visit appvance.ai/GENI and join the conversation on LinkedIn, X and Facebook.

About Appvance:

Appvance is the leader in generative AI for Software Quality. For the past decade, its flagship product AIQ has led the industry as an AI-first, unified software quality platform that delivers unprecedented levels of productivity to accelerate digital transformation in the enterprise. GENI ushers in a new era for Appvance and its customers – harnessing the power of AIQ to deliver fully autonomous AI-first software Quality Assurance and Testing. Leveraging generative AI and machine learning, AIQ can validate all likely user flows as well as generate new test cases and scripts from existing test cases to achieve complete application coverage™.